Predicting the outcome for patients with myelofibrosis undergoing an allogeneic hemopoietic stem cell transplant

Simona Sica*

*Autore corrispondente per questo lavoro

Risultato della ricerca: Contributo in rivistaArticolo in rivista

Abstract

Several predictive scores have been described for patients with myelofibrosis (MF): these include IPSS [1], DIPPS [2], MYSEC [3], MIPSS [4] and GIPSS [5]. All of these have in common the identification of clinical, and biological risk factors for evolution of the disease and death. When these prognostic scores are applied to patients undergoing a hemopoietic stem cell transplant (HSCT), the outcome reflects the progression of the disease: patients with an early disease, always do better than patients with more advanced disease, and/or a higher risk score [6, 7]. The question is the following: can we identify a prognostic score, specifically designed for patients undergoing an allogeneic HSCT. A recent study has identified transplant and molecular characteristics predictive of transplant outcome, and is referred to as the MTSS or molecular and transplant scoring system. These include: age over 57, Karnovsky score < 90%, platelet counts < 150 × 10^9/L, leukocyte count > 25 × 10^9/L, an HLA mismatched donor, ASXL1 mutation, and non-CARL/MP genotype, to be independent predictors of outcome [8], The Authors incorporate these factors in 4 level MTSS, low (0–2), intermediate (3–4), high (5) and very high (>5). The OS at 5 years for these groups was 90% (low), 77% (intermediate), 50% (high) and 34% (very high). However, there is no mention of relapse in this study, and thus one wonders why introduce molecular prognostication.
Lingua originaleEnglish
pagine (da-a)7-12
Numero di pagine6
RivistaBlood Cancer Journal
Volume12
DOI
Stato di pubblicazionePubblicato - 2022

Keywords

  • Predicting the outcome for patients with myelofibrosis undergoing an allogeneic hemopoietic stem cell transplant

Fingerprint

Entra nei temi di ricerca di 'Predicting the outcome for patients with myelofibrosis undergoing an allogeneic hemopoietic stem cell transplant'. Insieme formano una fingerprint unica.

Cita questo